PDA and BioPhorum have partnered to form a task force whose goal was to provide the industry and regulators with scientific data and analysis on the potential risks and benefits of implementing PUPSIT to improve sterility assurance. This webinar will describe the data generated by the task force studies and discuss considerations and best practices when implementing PUPSIT.
In this webinar, you will learn:
Janmeet Anant, Ph.D.
Merck
Senior Regulatory Consultant
Janmeet Anant is a senior regulatory consultant, focused on biopharmaceutical manufacturing at Merck. Janmeet serves as an executive board member for the Bioprocess Systems Alliance (BPSA) and a member of the Regulatory Governance Team at BioPhorum.
He has more than 20 years of experience, moving through technical application roles for chromatography, filtration, cell culture and, most recently, regulatory consulting. Janmeet has a B.S. in Chemistry and a Ph.D. in Pharmacology.
Andrew Koch
Merck
Technology Manager, Sterile Filtration
Andrew Koch is a customer applications specialist at Merck, supporting bioprocessing customers in sterile filtration with a focus on single-use redundant filtration and pre-use post-sterilization integrity testing. He has presented at several conferences and workshops on single-use final filtration assembly design. Andrew has a B.S. in medical biology from the University of New England and an MBA from Southern New Hampshire University.
Pharma and biopharma manufacturing
期间:45min
语言:English
场次 1:往期 March 18, 2021
如要继续阅读,请登录或创建帐户。
暂无帐户?